Replies to post #111490 on Biotech Values

[jq1234]

I'm not sure exactly what the line of demarcation is for the apparently different attitudes of the FDA, but they certainly seem more flexible in certain indications than others.

RA is a chronic disease where SOC is not as strongly established as oncology, thus individual patient treatment regimen is much more varied than oncology. There are room for mutiple oral RA drugs to share the market, just look at anti-TNF inhibitors.